| Sign In to gain access to subscriptions and/or personal tools. |
Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XRGlaxoSmithKline, New Frontier Science Park, Harlow, UK karen.hewett1{at}googlemail.com
Psychiatric Clinic, Academy of Medicine, Choroszcz, Poland
Department of Psychiatry, Psychosomatic Institute, Vienna, Austria
Department of Psychiatry, Klaara-Keskus, Helskinki, Finland
Department of Psychiatry, Alexander University Hospital, Sofia, Bulgaria
GlaxoSmithKline, New Frontier Science Park, Harlow, UK
GlaxoSmithKline, Research Triangle Park, NC, USA
GlaxoSmithKline, New Frontier Science Park, Harlow, UK
GlaxoSmithKline, Greenford, UK
GlaxoSmithKline, Research Triangle Park, NC, USA Abstract
The efficacy, safety and tolerability of bupropion XR and venlafaxine XR was assessed and compared with placebo in adult outpatients with major depressive disorder (MDD). Adults meeting DSM-IV criteria for MDD with a minimum Hamilton Depression Rating Scale (HAMD) 17-Item total score of
Key Words: bupropion XR • depression • venlafaxine XR
This version was published on July
1, 2009 Journal of Psychopharmacology, Vol. 23, No. 5,
531-538 (2009) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
18 were randomized to eight weeks of double-blind treatment with either bupropion XR (150 mg/day), venlafaxine XR (75 mg/day) or placebo. At the end of the fourth week of treatment, a dosage increase to bupropion XR 300 mg/day or venlafaxine XR 150 mg/day was allowed if, in the opinion of the investigator, response was inadequate. The primary efficacy endpoint was mean change from baseline at week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score last observation carried forward (LOCF). Mean changes from baseline at week 8 (LOCF) in MADRS total score were statistically significant for bupropion XR and venlafaxine XR patients compared to the placebo group: –16.0 for bupropion XR (P = 0.006 vs placebo), –17.1 for venlafaxine XR (P < 0.001 vs placebo) and –13.5 for placebo. Secondary outcomes (including CGI-S, HAM-A, MEI, Q-LES-Q-SF, responder and remitter analyses) also improved significantly for both active treatment groups compared with placebo. The most frequently reported adverse events were dry mouth and insomnia for bupropion XR, and nausea, hyperhidrosis, fatigue, and insomnia for venlafaxine XR. In this double-blind, placebo-controlled trial, bupropion XR at doses up to 300 mg/day and venlafaxine XR at doses up to 150 mg/day demonstrated comparable antidepressant efficacy.